Targeting the U.S. federal veterans' healthcare system as a key commercial channel for the CyPath Lung noninvasive lung cancer screening test, focusing on veterans with toxic military exposure histories covered under the PACT Act.

Expected impact: Drives accelerated institutional adoption and expands the commercial footprint of CyPath Lung into a federally funded patient cohort.

A 2,000-patient longitudinal clinical study designed to evaluate the clinical performance of the CyPath Lung flow cytometry test (investigational name FlowPath Lung) in high-risk individuals with existing lung nodules 6 mm to less than 30 mm in diameter.

Expected impact: Provides robust clinical validation to support future regulatory submissions and commercialization efforts.

A collaborative pilot study with Brooke Army Medical Center (BAMC) to evaluate the company's proprietary flow cytometry+AI platform to identify specific inflammatory biomarkers and biologic drug receptors (such as dupilumab and benralizumab) in sputum samples.

Expected impact: Expands the diagnostic platform beyond oncology into the $92 billion asthma and COPD treatment market by enabling precision medicine and treatment monitoring.

Discontinuing unprofitable pathology services (such as sexually transmitted infection testing) at the Precision Pathology Laboratory Services (PPLS) subsidiary to reduce labor and overhead costs.

Expected impact: Improves operating margins and sharpens focus on high-growth diagnostic offerings like CyPath Lung.